Lyell Immunopharma LYEL Cash Flow Statement (2020-2026)

NASDAQ LYEL
$14.37 +0.05 (+0.35%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Lyell Immunopharma Quarterly Cash Flow Statement

Periods 25 quarters
Latest Jun 2026

Lyell Immunopharma reported cash from operations of -$33.92M and free cash flow of -$34.08M for the quarter ended Jun 2026, up 1.6% year over year. This cash flow statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-48.89M-50.26M-73.55M-39.01M-64.19M0.64M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M-124.97M-42.07M-45.15M
Share-based Compensation
122.50M21.18M22.03M22.41M19.12M18.36M13.88M14.22M10.52M8.46M9.15M8.28M7.62M8.08M6.02M5.00M5.23M25.57M4.29M4.53M
Gains from Investment Securities
0.04M36.40M-0.03M5.00M10.00M2.92M13.00M
Asset Writedowns and Impairment
36.40M5.00M-5.00M51.30M1.44M
Cash from Operations
-25.49M-33.21M-47.85M-44.33M-37.10M-40.27M-46.21M-39.16M-37.69M-40.63M-42.02M-38.09M-35.04M-47.24M-54.74M-34.46M-28.58M-32.25M-38.51M-33.92M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
-0.55M-0.47M-0.47M-0.23M0.43M1.21M1.85M2.08M2.29M3.38M4.37M3.76M3.59M2.96M1.73M1.17M1.01M1.06M0.89M0.82M
Depreciation & Amortization (CF)Depreciation & Amortization
4.09M4.57M4.19M4.17M4.62M5.04M5.03M5.06M5.10M5.06M5.02M4.90M4.68M5.03M3.44M3.13M2.57M2.40M2.33M2.22M
Change in Working Capital
Change in Account Payables
-0.99M0.10M2.94M-1.77M0.02M-0.53M2.07M0.38M-1.41M0.42M-0.11M-0.52M-0.57M-2.04M-1.65M-0.23M-0.78M0.33M2.38M-1.46M
Change in Accured Expenses
1.94M4.22M-6.39M-0.77M1.32M5.37M-5.86M2.27M4.61M-1.74M-3.61M0.52M3.09M-1.25M-9.79M-3.33M0.57M4.90M-3.57M4.61M
Other Working Capital Changes
5.18M2.73M2.13M1.20M1.52M0.41M-1.05M0.30M-2.79M-0.59M0.84M1.61M-3.64M-2.00M-2.80M-0.42M2.39M-0.09M-3.23M
Investing Activities
Capital Expenditures
11.60M10.27M9.73M7.17M2.79M4.58M1.53M0.93M0.20M0.03M0.22M0.14M0.06M0.04M0.25M0.17M0.06M0.30M0.19M0.15M
Sales of Property, Plant and Equipment
0.26M0.02M
Change in Acquisitions & Divestments
142.04M70.33M79.81M121.85M106.50M110.90M142.25M187.10M178.15M156.12M130.03M161.80M133.41M123.70M154.12M93.52M74.14M52.91M54.65M69.39M
Cash from Investing Activities
-144.91M-73.86M-26.12M25.02M-57.09M46.65M32.15M152.91M99.67M-100.69M21.99M45.01M1.92M53.51M69.47M12.65M3.35M-31.36M17.38M15.62M
Financing Activities
Other financing activities
-1.06M2.56M1.57M5.13M0.33M1.16M0.73M0.10M0.71M0.44M0.18M0.18M0.03M0.50M
Change in Capital Stock
Net Equity Issued and Repurchased
50.00M50.00M
Misc.
Cash from Financing Activities
-0.53M7.40M2.56M2.46M4.76M0.86M-0.07M1.20M-0.14M0.76M0.03M0.86M0.44M0.00M0.18M50.00M0.22M51.72M0.52M
Change in Cash
-170.94M-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M-17.78M
Free Cash Flow
-37.09M-43.48M-57.59M-51.50M-39.89M-44.85M-47.74M-40.09M-37.88M-40.66M-42.24M-38.23M-35.10M-47.29M-54.98M-34.63M-28.64M-32.55M-38.70M-34.08M
Net Cash Flow
-170.94M-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M-17.78M